Prospects for the treatment of drug-resistant malaria parasites

被引：19

作者：

Tilley, Leann ^{[1
]}

Davis, Timothy M. E.

Bray, Patrick G.

机构：

[1] La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia

[2] Univ Western Australia, Sch Med & Pharmacol, Fremantle, WA, Australia

[3] Univ Liverpool, Liverpool Sch Trop Med, Mol & Biochem Parasitol Grp, Liverpool L3 5QA, Merseyside, England

来源：

FUTURE MICROBIOLOGY | 2006年 / 1卷 / 01期

关键词：

antimalarials; artemisinin combination therapy; chloroquine; drug resistance; endoperoxide; malaria; PfCRT; quinolines;

D O I：

10.2217/17460913.1.1.127

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Widespread parasitic resistance has led to an urgent need for the development and implementation of new drugs for the treatment of Plasmodium foiciparum malaria. Artemisinin and its derivatives are becoming increasingly important, used preferably in combination with a second antimalarial agent to increase the efficacy and slow the development of resistance. However, cost, production and pharmacological issues associated with artemisinin derivatives and potential partner drugs are hindering the implementation of combination therapies. This article reviews the molecular basis of the action of, and resistance to, different antimalarials and examines the prospects for the next generation of drugs to combat this potentially lethal human pathogen.

引用

页码：127 / 141

页数：15

共 147 条

[1]

Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8

[2] Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (Encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10 [J].